MedTrace Logo

SMS HPV Vaccine Reminders

NCT05151367 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2024-07-08

Study results available
· View outcomes & findings →

Summary

This study will take place at health centres and their affiliated schools and community immunization centers overseen by the Kampala Capital City Authority (KCCA) as well as at the Makerere/Mulago/Columbia Adolescent Health Clinic, also in Kampala. While text messages can be used in populations with low literacy, families can opt to receive automated phone call reminders instead. The investigators will pilot assess the impact of vaccine reminders on human papillomavirus (HPV) vaccination. Caregivers of preteens/adolescents will be randomized and stratified by site, language and HPV vaccine dose needed (initiation vs. completion). As this is a feasibility trial, the investigators expect to measure effect size but not necessarily achieve statistical significance.

Conditions

  • Human Papillomavirus Vaccination

Interventions

BEHAVIORAL

Text message reminder

Receipt of text messages notifying when the next HPV vaccine dose is due (either first or second)

Sponsors & Collaborators

  • Makerere University

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • Columbia University

    lead OTHER

Principal Investigators

  • Melissa S. Stockwell, MD, MPH · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
14 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-23
Primary Completion
2022-10-30
Completion
2022-12-31

Countries

  • United States
  • Uganda

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05151367 on ClinicalTrials.gov